Gilead is nearing a deal to buy biotech Immunomedics and its prized breast-cancer drug for more than $20 billion, say people familiar with the matter
Gilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion, according to people familiar with the matter.
Immunomedics has a market value of roughly $10 billion following a recent surge in its stock, meaning that Gilead is paying up to secure ownership of the company.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
WSJ News Exclusive | SoftBank Nears $40 Billion Deal to Sell Arm Holdings to NvidiaThe Japanese technology conglomerate is nearing another big asset sale—a deal selling Arms Holdings to Nvidia for more than $40 billion, according to people familiar with the matter.
Read more »
SoftBank nears deal to sell Arm Holdings to Nvidia for more than $40 billion - WSJSoftBank Group Corp is nearing a deal to sell British chip designer Arm Holdings to Nvidia Corp for more than $40 billion, the Wall Street Journal reported on Saturday, citing sources.
Read more »
WSJ News Exclusive | Second Top Female Executive at Bridgewater Says Firm Paid Her Less Than MenBridgewater's top female executive is sparring with the firm after learning she earned less than male counterparts, people familiar with the matter said
Read more »
WSJ News Exclusive | Tommy Hilfiger Asks $47.5 Million for Greenwich EstateAt a time when New Yorkers fleeing the pandemic are driving up Greenwich property values, Tommy Hilfiger is listing yet another Greenwich home, a sprawling French Normandy-style estate, for $47.5 million
Read more »
WSJ News Exclusive | Rural California Counties Accuse Newsom of Withholding Covid-19 FundsLeaders of some rural California counties are accusing Gov. Gavin Newsom of improperly withholding federal coronavirus relief funds to force them to slow business reopenings.
Read more »